Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: EC:4.1.2.13 (aldolase)
 3,461 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

A specific radioimmunoassay was developed for the quantitation of human muscle type aldolase (M-ALD) in human serum. The amount of M-ALD antigen present in 135 sera from normal healthy subjects, noncancer patients and cancer patients was determined. The serum M-ALD value for the 41 normal healthy subjects averaged 171 +/- 39 ng/ml and they had a range from 130 ng/ml to 210 ng/ml. In 33 noncancer hospital patients, excluding patients with muscle diseases, the serum M-ALD values averaged 164 ng/ml and had a range of 125 to 220 ng/ml. In contrast the 61 cancer patients had serum M-ALD values which averaged 586 ng/ml and had a range of 85 to 5800 ng/ml. Eighty two percent of the cancer patients had serum concentrations of M-ALD which were outside of the normal range. The CEA value was determined in the serum of the cancer patients and thirty five percent of the patients had elevated serum concentrations. The measurement of M-ALD values in human serum may be an additional laboratory test in the diagnosis and follow up of the cancer patients.
 ...
PMID:[Clinical study on aldolase isoenzyme--the development of the method of cancer diagnosis with muscle type aldolase (author's transl)]. 23 Oct 1

It is known that the serum in cancer patients has the characteristics of the heat-stability. The factor produce the heat-stability is known to be due to tumor marker(TM) such as CEA, CA125(glycoprotein), CA19-9, CA15-3, SLX, CA50, CA72-4, DU-PAN-2, ST-439, SPAN-1(mucin) and alpha 1-acid glycoprotein, IAP(acute reactants). CEA belongs to IgG supergene family protein and is not oncofetal protein. CA19-9 is synthesis in subjects with Le(a) or Le(b) type, but negative in Le(a- b-) type. Thus, CA19-9 is not available as TM in Le(a- b-) type. Many TMs can be classified in 3 types because cancer cell has the character of immature cells which composed of immature proteins or glycoproteins. (1) Oncofetal protein: AFP(fetal albumin), PTHrP(fetal PTH) (2) The immature isozyme type: increase of amylase(salivary type), CPK(brain type) and aldolase (muscle and brain type) (3) The immature protein in biosynthesis process: increase of precursor protein(prepro type or pro type) such as PIVKA-II(preprothrombin), ProGRP, TPA or CYFRA 21-1(pro-keratin?) and hormone precursor in hormone producing tumor.
 ...
PMID:[Tumor marker--present and future]. 931 Dec 62